By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

The New England Journal of Medicine 

10 Shattuck Street

Boston  Massachusetts  02115-6094  U.S.A.
Phone: 617-734-9800 Fax: 617-739-9864


SEARCH JOBS


Industry
Services

Segment
Publisher





Company News
Hiding Data And Other Criticisms Of Big Pharma, The New England Journal of Medicine Reveals 4/24/2017 6:14:50 AM
NIH Study In The New England Journal of Medicine Shows Novartis Drug Eltrombopag As First-Line Therapy With Standard Treatment Improves Responses In Severe Aplastic Anemia 4/20/2017 10:21:54 AM
NIH Study In The New England Journal of Medicine Shows Novartis AG (NVS) Drug Eltrombopag As First-Line Therapy With Standard Treatment Improves Responses In Severe Aplastic Anemia 4/20/2017 6:37:35 AM
The New England Journal of Medicine Publishes Pivotal Phase III Data For CSL Behring's Subcutaneous C1-Esterase Inhibitor In HAE Patients 3/23/2017 6:16:33 AM
The OHSU Knight Cancer Institute Release: "The New England Journal of Medicine" Publishes Long-Term Results Of GleevecĀ® For Patients With Chronic Myeloid Leukemia 3/9/2017 9:21:53 AM
bluebird bio (BLUE) Announces Publication Of Case Study On First Patient With Severe Sickle Cell Disease Treated With Gene Therapy In The New England Journal of Medicine 3/2/2017 6:56:44 AM
Chugai Pharma's Anti-IL-31 Receptor A Humanized Monoclonal Antibody "Nemolizumab (CIM331)" Global Phase II Study Data Published In The New England Journal of Medicine Online 3/2/2017 6:47:14 AM
The New England Journal of Medicine Publishes Phase Ib Results For Shire (SHPG)'s Investigational Treatment For Hereditary Angioedema, A Rare Genetic Disease 2/23/2017 7:36:01 AM
The New England Journal of Medicine Publishes Five-Year Data From Ethicon (JNJ)-Funded STAMPEDE Study 2/16/2017 7:20:27 AM
Eli Lilly (LLY) Release: Additional Results From Pivotal RA-BEAM Study Published In The New England Journal of Medicine Show Baricitinib-Treated Patients Demonstrated Sustained Improvement In Rheumatoid Arthritis Compared To Adalimumab And Placebo 2/16/2017 7:17:50 AM
12345678910...
//-->